Dr. Weijiang Liang 梁卫江
Chief Physician, Associate Professor
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and treatment of gynecologic tumors (ovarian cancer, cervical cancer), germ cell tumors, and teratomas.
Dr. Liang holds a medical doctorate and completed postdoctoral research at Sun Yat-sen University. A chief physician and master’s supervisor, Dr. Liang specializes in clinical oncology and applied basic research. Dr. Liang has led projects funded by the Guangdong Natural Science Foundation and China Postdoctoral Science Foundation, participated in national major projects, and published over 40 papers as first or corresponding author.
Professional roles
- Vice Chair, Guangdong Branch of the Chinese Medical Association
- Vice Chair, Chemotherapy Professional Committee, Guangzhou Anti-Cancer Association
- Member, Oncology Group, Obstetrics and Gynecology Branch, Guangdong Medical Association
- Vice Chair, Tumor Psychology Professional Committee, Guangdong Association of Integrative Traditional Chinese and Western Medicine
Name order: in Chinese the family name comes first (Liang Weijiang). Papers usually list the name as Weijiang Liang or Liang W.
Selected publications
21 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- PeerJ, 2022 (senior author): Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in female patients with breast cancer or genitalia malignancies. PubMed 35769138
- Nan Fang Yi Ke Da Xue Xue Bao, 2018 (senior author): [Silencing of SLP-2 inhibits the migration and invasion of cervical cancer cells in vitro]. PubMed 33168500
- Cancer Sci, 2018 (senior author): Stomatin-like protein 2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and the mitochondrial apoptosis pathway in cervical cancer cells. PubMed 29516570
- Oncol Lett, 2017 (senior author): Stomatin-like protein 2 is overexpressed in cervical cancer and involved in tumor cell apoptosis. PubMed 29181097
- Oncol Lett, 2017 (senior author): Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. PubMed 28927091
- Cancer Cell Int, 2017 (senior author): Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. PubMed 28507454
- Tumour Biol, 2015 (senior author): Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. PubMed 26063409
- Gynecol Obstet Invest, 2015 (senior author): Prognostic significance of pretreatment plasma fibrinogen and platelet levels in patients with early-stage cervical cancer. PubMed 25278089
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion